SARAH S. VANCE, Chair
Before the Panel :
Plaintiffs in five actions support the Section 1407 motion in its entirety. Plaintiff in the first-filed Eastern District of Kentucky action (Taylor ) supports centralization in the Northern District of California or, alternatively, the Eastern District of Kentucky. Defendants Astrazeneca Pharmaceuticals LP, Bristol-Myers Squibb Co., and McKesson Corp. oppose centralization and, alternatively, suggest that the Southern District of California be selected as the transferee district. If that district is not available, then the defendants suggest centralization in the Eastern or Western Districts of Kentucky or the Northern District of Georgia.
On the basis of the papers filed and the hearing session held, we find that these actions involve common questions of fact, and that centralization under Section 1407 in the Eastern District of Kentucky will serve the convenience of the parties and witnesses and promote the just and efficient conduct of this litigation. All actions share numerous factual questions, inasmuch as plaintiffs allege that the use of Onglyza or Kombiglyze XR caused them or their decedent to develop heart failure or other conditions such as congestive heart failure, myocardial infarction and/or cardiovascular injury. Centralization will eliminate duplicative discovery; prevent inconsistent pretrial rulings (particularly on such matters as preemption of plaintiffs' claims and Daubert rulings); and conserve the resources of the parties, their counsel, and the judiciary.
Defendants oppose transfer by arguing that plaintiffs' allegations are supported by a single study (the SAVOR study), which itself supports only claims regarding heart failure -not the various other injuries (congestive heart failure, acute hypoxic respiratory failure, coronary artery disease and cardiovascular injury ) plaintiffs allege. They argue that, as a consequence, these cases likely will turn on unique issues that are applicable to, at most, a small subset of other cases. Defendants also assert that informal coordination among the actions is a feasible alternative to centralization. These objections are insufficient to overcome the significant advantages that centralization will afford. To date, there are 84 cases pending in over 30 districts. Informal coordination among 84 cases scattered across the nation does not seem feasible (even if, as defendants argue, there are a dozen cases pending in the District of New Jersey that are ripe to be dismissed for failure to serve defendants). Defendants concede that most cases involve allegations of heart failure, which is squarely in line with the results of the SAVOR study and the subsequent label change for Onglyza and Kombiglyze XR in April 2016. If defendants are convinced *1359that plaintiffs' claims regarding heart failure or other injuries lack scientific support, then centralization affords them a single forum in which to seek summary judgment, which might be applied to other similar cases. Centralization also will provide a single forum where disputes about the sufficiency of defendants' past and any supplemental document productions, as well as about expert discovery, can be handled in a streamlined fashion.
Given that the drugs at issue here were marketed nationwide, and no action or group of actions is significantly advanced, any number of potential transferee districts would be appropriate. We select the Eastern District of Kentucky, a relatively accessible district that is supported by defendants and certain plaintiffs, as transferee district for this litigation. The longest-pending action (Taylor ) is proceeding apace in this district. We are confident that Chief Judge Karen K. Caldwell will steer this litigation on a prudent course.
IT IS THEREFORE ORDERED that pursuant to 28 U.S.C. § 1407, the actions listed on Schedule A and pending outside the Eastern District of Kentucky are transferred to the Eastern District of Kentucky and, with the consent of that court, assigned to the Honorable Karen K. Caldwell for coordinated or consolidated pretrial proceedings with the actions pending in that district and listed on Schedule A.
SCHEDULE A
MDL No. 2809 - IN RE: ONGLYZA (SAXAGLIPTIN) AND KOMBIGLYZE XR (SAXAGLIPTIN AND METFORMIN) PRODUCTS LIABILITY LITIGATION
Middle District of Alabama
VALLENTINE v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 3:17-00265
Northern District of Alabama
PEOPLES v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 5:17-00101
District of Arizona
SETTLE v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 2:17-01269
Northern District of California
WILLIAMS, ET AL. v. ASTRAZENECA PHARMACEUTICALS LP, ET AL., C.A. No. 3:16-07152
MARTIN v. BRISTOL-MYERS COMPANY, ET AL., C.A. No. 3:17-00661
Northern District of Georgia
REID v. BRISTOL-MEYERS SQUIBB COMPANY, ET AL., C.A. No. 1:17-01503
TURNER v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 1:17-02782
YORK v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 1:17-02915
JOHNSON v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 1:17-02916
District of Idaho
CHRISTENSEN v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 1:17-00321
Northern District of Indiana
MILLER v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 1:17-00330
*1360Southern District of Indiana
COUSINS v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 1:17-02607
Eastern District of Kentucky
BARNES v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 2:17-00124
TAYLOR, ET AL. v. BRISTOL-MYERS SQUIBB COMPANY, INC., ET AL., C.A. No. 5:16-00260
Western District of Kentucky
TUCKER v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 3:17-00268
Eastern District of Louisiana
Free access — add to your briefcase to read the full text and ask questions with AI
SARAH S. VANCE, Chair
Before the Panel :
Plaintiffs in five actions support the Section 1407 motion in its entirety. Plaintiff in the first-filed Eastern District of Kentucky action (Taylor ) supports centralization in the Northern District of California or, alternatively, the Eastern District of Kentucky. Defendants Astrazeneca Pharmaceuticals LP, Bristol-Myers Squibb Co., and McKesson Corp. oppose centralization and, alternatively, suggest that the Southern District of California be selected as the transferee district. If that district is not available, then the defendants suggest centralization in the Eastern or Western Districts of Kentucky or the Northern District of Georgia.
On the basis of the papers filed and the hearing session held, we find that these actions involve common questions of fact, and that centralization under Section 1407 in the Eastern District of Kentucky will serve the convenience of the parties and witnesses and promote the just and efficient conduct of this litigation. All actions share numerous factual questions, inasmuch as plaintiffs allege that the use of Onglyza or Kombiglyze XR caused them or their decedent to develop heart failure or other conditions such as congestive heart failure, myocardial infarction and/or cardiovascular injury. Centralization will eliminate duplicative discovery; prevent inconsistent pretrial rulings (particularly on such matters as preemption of plaintiffs' claims and Daubert rulings); and conserve the resources of the parties, their counsel, and the judiciary.
Defendants oppose transfer by arguing that plaintiffs' allegations are supported by a single study (the SAVOR study), which itself supports only claims regarding heart failure -not the various other injuries (congestive heart failure, acute hypoxic respiratory failure, coronary artery disease and cardiovascular injury ) plaintiffs allege. They argue that, as a consequence, these cases likely will turn on unique issues that are applicable to, at most, a small subset of other cases. Defendants also assert that informal coordination among the actions is a feasible alternative to centralization. These objections are insufficient to overcome the significant advantages that centralization will afford. To date, there are 84 cases pending in over 30 districts. Informal coordination among 84 cases scattered across the nation does not seem feasible (even if, as defendants argue, there are a dozen cases pending in the District of New Jersey that are ripe to be dismissed for failure to serve defendants). Defendants concede that most cases involve allegations of heart failure, which is squarely in line with the results of the SAVOR study and the subsequent label change for Onglyza and Kombiglyze XR in April 2016. If defendants are convinced *1359that plaintiffs' claims regarding heart failure or other injuries lack scientific support, then centralization affords them a single forum in which to seek summary judgment, which might be applied to other similar cases. Centralization also will provide a single forum where disputes about the sufficiency of defendants' past and any supplemental document productions, as well as about expert discovery, can be handled in a streamlined fashion.
Given that the drugs at issue here were marketed nationwide, and no action or group of actions is significantly advanced, any number of potential transferee districts would be appropriate. We select the Eastern District of Kentucky, a relatively accessible district that is supported by defendants and certain plaintiffs, as transferee district for this litigation. The longest-pending action (Taylor ) is proceeding apace in this district. We are confident that Chief Judge Karen K. Caldwell will steer this litigation on a prudent course.
IT IS THEREFORE ORDERED that pursuant to 28 U.S.C. § 1407, the actions listed on Schedule A and pending outside the Eastern District of Kentucky are transferred to the Eastern District of Kentucky and, with the consent of that court, assigned to the Honorable Karen K. Caldwell for coordinated or consolidated pretrial proceedings with the actions pending in that district and listed on Schedule A.
SCHEDULE A
MDL No. 2809 - IN RE: ONGLYZA (SAXAGLIPTIN) AND KOMBIGLYZE XR (SAXAGLIPTIN AND METFORMIN) PRODUCTS LIABILITY LITIGATION
Middle District of Alabama
VALLENTINE v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 3:17-00265
Northern District of Alabama
PEOPLES v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 5:17-00101
District of Arizona
SETTLE v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 2:17-01269
Northern District of California
WILLIAMS, ET AL. v. ASTRAZENECA PHARMACEUTICALS LP, ET AL., C.A. No. 3:16-07152
MARTIN v. BRISTOL-MYERS COMPANY, ET AL., C.A. No. 3:17-00661
Northern District of Georgia
REID v. BRISTOL-MEYERS SQUIBB COMPANY, ET AL., C.A. No. 1:17-01503
TURNER v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 1:17-02782
YORK v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 1:17-02915
JOHNSON v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 1:17-02916
District of Idaho
CHRISTENSEN v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 1:17-00321
Northern District of Indiana
MILLER v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 1:17-00330
*1360Southern District of Indiana
COUSINS v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 1:17-02607
Eastern District of Kentucky
BARNES v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 2:17-00124
TAYLOR, ET AL. v. BRISTOL-MYERS SQUIBB COMPANY, INC., ET AL., C.A. No. 5:16-00260
Western District of Kentucky
TUCKER v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 3:17-00268
Eastern District of Louisiana
ROSS v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 2:17-00443
LESTER SPEIGHTS v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 2:17-07884
Middle District of Louisiana
BROWN v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 3:17-00039
Western District of Louisiana
LETELL v. BRISTOL-MYERS SQUIBB CO., ET AL., C.A. No. 2:17-00553
District of New Jersey
YOUNG v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 3:17-00347
REEVES, ET AL. v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 3:17-03024
MITCHELL v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 3:17-03026
BINNS v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 3:17-03028
TALTON v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 3:17-03029
MCAFEE v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 3:17-03030
GREEN v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 3:17-03032
ISHMAN v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 3:17-03033
ATKINS, SR. v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 3:17-03034
DAY v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 3:17-03035
ASENCIO v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 3:17-03036
SECHLER, ET AL. v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 3:17-03037
Middle District of North Carolina
HOLLAND v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 1:17-00710
Southern District of Ohio
CARPENTER v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 1:17-00262
*1361Eastern District of Oklahoma
HULBERT v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 6:17-00327
District of South Carolina
DUBOSE v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 4:17-01695
Eastern District of Tennessee
CAMPBELL v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 1:17-00219
Middle District of Tennessee
WILCOX v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 3:17-01202
Eastern District of Texas
WARE v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 1:17-00111
Northern District of Texas
BOLLER v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 4:17-00050
Southern District of Texas
DAVILA v. BRISTOL-MYERS SQUIBB COMPANY, ET AL., C.A. No. 2:17-00145
CHESTER v. BRISTOL-MEYERS SQUIBB COMPANY, ET AL., C.A. No. 4:17-00316
Judge Ellen Segal Huvelle took no part in the decision of this matter.